This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| caveolin-1 | |
|---|---|
| Name | Caveolin-1 |
| Uniprot | P49817 |
| Organism | Homo sapiens |
caveolin-1 is a membrane-associated scaffolding protein primarily known for its role in the formation of caveolae, specialized invaginations of the plasma membrane. First characterized in studies that involved researchers associated with institutions such as Harvard University, Stanford University, Massachusetts Institute of Technology, University of Cambridge, and Max Planck Society, caveolin-1 has been investigated across disciplines including cell biology, biochemistry, and medicine. It has become central to research programs at organizations like the National Institutes of Health, Wellcome Trust, and European Molecular Biology Laboratory.
Caveolin-1 is a ~21–24 kDa protein encoded by a gene studied in laboratories at Cold Spring Harbor Laboratory, Salk Institute, Johns Hopkins University, University of Oxford, and University of California, San Francisco. Structural characterization employed techniques pioneered at Laboratory of Molecular Biology, European Synchrotron Radiation Facility, Brookhaven National Laboratory, Lawrence Berkeley National Laboratory, and Argonne National Laboratory. The protein contains an N-terminal oligomerization domain, a central intramembrane domain that forms a hairpin, and a C-terminal scaffolding domain; these features were elucidated using methods developed by groups associated with Nobel Prize in Chemistry laureates and institutions such as Max Planck Institute for Biophysical Chemistry. Biophysical studies referenced paradigms from James Watson, Francis Crick, Rosalind Franklin, Linus Pauling, and Dorothy Hodgkin-style structural inference. Post-translational modifications include palmitoylation and phosphorylation at conserved residues, characterized using mass spectrometry facilities at Center for Genomic Regulation, EMBL-EBI, and Proteomics Unit of the University of Copenhagen.
The gene encoding caveolin-1, CAV1, was mapped and cloned in projects involving consortia like Human Genome Project, ENCODE Project Consortium, 1000 Genomes Project, International HapMap Project, and research groups at Broad Institute and Wellcome Sanger Institute. Expression profiling across tissues was performed using platforms developed at Affymetrix, Illumina, Inc., Agilent Technologies, and bioinformatics pipelines from European Bioinformatics Institute. Regulatory elements in the CAV1 locus were analyzed in studies referencing transcription factor datasets associated with ENCODE Project Consortium and chromatin architecture insights from Hi-C mapping pioneered by groups at MIT and Harvard Medical School. Differential expression has been reported in contexts investigated at Mayo Clinic, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, and in cohort studies coordinated with World Health Organization frameworks.
Caveolin-1 localizes to caveolae at the plasma membrane, a discovery linked to electron microscopy techniques refined at Bell Labs, Rockefeller University, Pasteur Institute, University of Turku, and Karolinska Institutet. Within cells, caveolin-1 participates in endocytic processes and mechanotransduction studied in laboratories affiliated with Imperial College London, University of Pennsylvania, Yale University, Columbia University, and Rice University. Functional assays incorporating paradigms from Alexis Carrel, Christian de Duve, George Palade, and Keith Porter clarified roles in vesicular trafficking, lipid homeostasis, and membrane curvature. Interaction with cytoskeletal elements observed in work from University College London, ETH Zurich, and University of Chicago links caveolin-1 to cellular stiffness and signal compartmentalization.
Caveolin-1 is a principal component of membrane microdomains often termed lipid rafts, connecting to signaling networks explored by researchers at Scripps Research Institute, Cold Spring Harbor Laboratory, Johns Hopkins University School of Medicine, National Cancer Institute, and Dana-Farber Cancer Institute. It modulates receptors and kinases studied in pathways involving proteins characterized by groups at European Molecular Biology Laboratory, Howard Hughes Medical Institute, Rockefeller University, and Karolinska Institutet. Studies linking caveolin-1 to G-protein coupled receptor signaling, receptor tyrosine kinases, and nitric oxide synthase referenced paradigms from Nobel Prize in Physiology or Medicine recipients and labs including University of California, Los Angeles and University of Michigan. Lipid interactions incorporate cholesterol binding themes explored in projects funded by Medical Research Council (UK), National Science Foundation, and European Research Council.
Physiological roles of caveolin-1 span vascular biology, adipocyte function, pulmonary physiology, and fibroblast activity, with clinical and basic research from Mayo Clinic, Cleveland Clinic, Brigham and Women's Hospital, Johns Hopkins Hospital, and UCLA Medical Center. Tissue distribution was cataloged in atlases produced by Human Protein Atlas, Genotype-Tissue Expression Project, Allen Institute for Brain Science, ProteomicsDB, and databases maintained at European Bioinformatics Institute. Animal model studies at facilities such as The Jackson Laboratory, European Mouse Mutant Archive, and Riken BioResource Center linked caveolin-1 deficiency to phenotypes in cardiovascular, metabolic, and pulmonary systems documented by multicenter consortia including International Mouse Phenotyping Consortium.
Alterations in caveolin-1 expression or function have been implicated in cancer, pulmonary arterial hypertension, lipodystrophy, and cardiovascular disease, with clinical investigations at MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Cleveland Clinic, Stanford Health Care, and Johns Hopkins Medicine. Genetic studies referencing databases like ClinVar, OMIM, dbSNP, and cohorts from UK Biobank and Framingham Heart Study associated CAV1 variants with disease susceptibility. Therapeutic research incorporating strategies from NIH, Bill & Melinda Gates Foundation, Wellcome Trust, and pharmaceutical companies including Roche, Pfizer, Novartis, and GlaxoSmithKline explored targeting caveolin-1-mediated pathways.
Caveolin-1 binds numerous proteins including signaling molecules, scaffolding partners, and lipid-interacting enzymes, with interaction maps assembled using resources such as BioGRID, STRING, IntAct, Reactome, and KEGG. Experimental approaches from EMBL, ProteomeXchange, PRIDE Archive, Cold Spring Harbor Laboratory, and Max Planck Institute identified partners in pathways studied by laboratories at Harvard Medical School, University of Cambridge, Stanford University School of Medicine, and Columbia University Irving Medical Center. Binding studies implicated caveolin-1 interactions in complexes relevant to oncology, vascular biology, and metabolic regulation, informing translational projects at institutions like FDA-linked research centers and global consortia.
Category:Membrane proteins Category:Scaffolding proteins Category:Human proteins